Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) announced that Professor Mok Shu Kam, Tony will retire and not seek re-election at the AGM on May 12, 2026, ceasing his role as Independent Non-executive Director and as chair/member of board committees due to nearing the nine-year tenure cap under Hong Kong Listing Rules.
Effective at the conclusion of the AGM and subject to re-election of directors, the Board approved committee changes: Dr Renu Bhatia appointed Senior and Lead Independent Non-executive Director and Nomination Committee chair; Dr Chaohong Hu appointed Technical Committee chair; and Professor Tan Shao Weng, Daniel joined the Sustainability Committee.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) reported 2025 results with net income attributable of $456.9 million and a year-end cash balance of $1.4 billion, driven largely by a $415.8 million post-tax divestment gain. Total in-market sales reached $524.7 million (+5%), led by FRUZAQLA® sales of $366.2 million (+26%). Consolidated revenue was $548.5 million (-13%) as oncology consolidated revenue declined to $214.4 million (-21%).
The company advanced its ATTC platform, dosing first patient for HMPL-A251 in December 2025 and initiating further ATTC trials in 2026, while multiple late-stage programs and regulatory filings progressed.
HUTCHMED (Nasdaq/AIM:HCM) initiated a first-in-human Phase I/IIa trial of HMPL-A580 on March 4, 2026. HMPL-A580 is the company’s second Antibody-Targeted Therapy Conjugate (ATTC), combining a PI3K/PIKK inhibitor payload with an anti-EGFR antibody.
The multicenter, open-label study in China and the US will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with a Phase I dose-escalation to find the maximum tolerated dose and a Phase IIa expansion to further characterize activity. ClinicalTrials.gov identifier NCT07396584.
HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) will announce its final results for the year ended December 31, 2025 on Thursday, March 5, 2026.
Management will host two webcast presentations for analysts and investors with Q&A. The English webcast is at 8:00 am EST and the Chinese (Putonghua) webcast at 8:30 am HKT. Slides and replays will be available via the company website.
HUTCHMED (Nasdaq/AIM: HCM) highlighted that results from the randomized Phase III SACHI trial were published in The Lancet on Jan 14, 2026, confirming efficacy of MET inhibition in advanced EGFR‑mutant NSCLC with acquired MET amplification after progression on prior EGFR‑TKI therapy.
The trial evaluated the oral combination of savolitinib (ORPATHYS) plus osimertinib (TAGRISSO). Based on interim SACHI data, the savolitinib+osimertinib combination received regulatory approval in China in June 2025. The program is jointly developed by AstraZeneca and HUTCHMED.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that the Phase III registration part of the ESLIM-02 trial of sovleplenib, a Syk inhibitor for adult warm antibody autoimmune hemolytic anemia (wAIHA) in China, met its primary endpoint of durable hemoglobin response during weeks 5–24.
The randomized, double‑blind, placebo‑controlled study enrolled patients with primary or secondary wAIHA who relapsed or were refractory to ≥1 prior standard therapy. Earlier Phase II data reported overall response 43.8% vs 0% at 8 weeks and 66.7% at 24 weeks for sovleplenib with a favourable safety profile. HUTCHMED plans to submit a NDA to NMPA in H1 2026. Full ESLIM-02 results will be presented at an upcoming scientific conference.
HUTCHMED (Nasdaq/AIM: HCM) has initiated the Phase III portion of its Phase II/III trial evaluating surufatinib + camrelizumab + nab-paclitaxel + gemcitabine (S+C+AG) as first-line treatment for metastatic pancreatic ductal adenocarcinoma in China, with the first patient dosed on Dec 30, 2025.
The Phase III plans ~400 additional patients (62 in Phase II). Primary endpoint is overall survival (OS). Phase II results showed median PFS 7.20 vs 5.52 months (HR 0.499, p=0.0407), ORR 67.7% vs 41.9% (p=0.0430) and DCR 93.5% vs 71.0% (p=0.0149). OS was immature (not reached vs 8.48 months, unstratified HR 0.555). Safety: grade ≥3 TEAEs 80.6% vs 61.3%.
HUTCHMED (Nasdaq/AIM: HCM) announced that the China NMPA accepted the NDA for savolitinib to treat locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma with MET amplification and granted priority review on Dec 30, 2025.
The NDA is supported by a single-arm, multi-center Phase II registration study in Chinese patients that met its primary endpoint of objective response rate (ORR) by IRC (RECIST 1.1). Savolitinib previously received Breakthrough Therapy designation in 2023. MET amplification is estimated at 4–6% of gastric cancer cases, with an annual incidence of roughly 18,000 patients in China.
HUTCHMED (Nasdaq/AIM: HCM) announced that the New Drug Application for fanregratinib (HMPL-453) in second-line intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement has been accepted and granted priority review by the China NMPA on Dec 29, 2025. Fanregratinib is an oral selective FGFR 1/2/3 inhibitor.
The NDA is supported by a single-arm, multi-center Phase II registration study in China (clinicaltrials.gov identifier NCT04353375) that met its primary endpoint of objective response rate; secondary endpoints (PFS, DCR, DoR, OS) also supported the primary findings. ICC accounts for roughly 8.2–15.0% of primary liver cancers and has an approximate 5-year overall survival of 9%; ~10–15% of ICC tumors harbor FGFR2 fusions/rearrangements.
HUTCHMED (NASDAQ/AIM: HCM) initiated global Phase I/IIa clinical development of HMPL-A251, the first clinical candidate from its next-generation ATTC platform. The first patient was dosed in China on Dec 16, 2025, with study sites in the US and China and registry identifier NCT07228247. HMPL-A251 is a HER2-targeted Antibody-Targeted Therapy Conjugate carrying a highly selective PI3K/PIKK inhibitor payload via a cleavable linker. The open-label study will evaluate safety, tolerability, MTD/RDE, and preliminary efficacy, plus pharmacokinetics and immunogenicity in HER2-expressing solid tumors.
Preclinical data were presented at the 2025 AACR-NCI-EORTC conference.